Expression level of beta protein 1 mRNA in Chinese breast cancer patients: A potential molecular marker for poor prognosis

Cancer Science

Volumn 99, Issue 1, 2008, Pages 173-178

  Yu, Man ^a,b,c   Yang, Yi ^a   Shi, Yurong ^a   Wang, Defa ^d   Wei, Xiyin ^a   Zhang, Ning ^a,e   Niu, Ruifang ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d NANKAI UNIVERSITY   (China)

^e OAKLAND UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA PROTEIN1; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; GOSERELIN; MESSENGER RNA; METHOTREXATE; ONCOPROTEIN; TAMOXIFEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER GRADING; CANCER GROWTH; CHINESE; CONTROLLED STUDY; FEMALE; GROWTH RATE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; AGED; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; FLUOROURACIL; GOSERELIN; HOMEODOMAIN PROTEINS; HUMANS; METHOTREXATE; MICE; MICE, SCID; MIDDLE AGED; PROGNOSIS; RNA, MESSENGER; TAMOXIFEN; TRANSCRIPTION FACTORS;

EID: 36949007935     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00661.x     Document Type: Article

References (34)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Bray F, McCarron P, Parkin DM. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 2004; 6: 229-39.
3. Yang L, Parkin DM, Ferlay J, Li L, Chen Y. Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev 2005; 14: 243-50.
4. Newman LA, Mamounas EP. Review of breast cancer clinical trials conducted by the National Surgical Adjuvant Breast Project. Surg Clin North Am 2007; 87: 279-305.
5. Early Breast Cancer Trialists'Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005; 365: 1687-717.
6. Lewis MT. Homeobox genes in mammary gland development and neoplasia. Breast Cancer Res 2000; 2: 158-69.
7. Samuel S, Naora H. Homeobox gene expression in cancer: Insights from developmental regulation and deregulation. Eur J Cancer 2005; 41: 2428-37.
8. Abate-Shen C. Deregulated homeobox gene expression in cancer: Cause or consequence? Nat Rev Cancer 2002; 2: 777-85.
9. Henderson GS, van Diest PJ, Burger H, Russo J, Raman V. Expression pattern of a homeotic gene, HOXA5, in normal breast and in breast tumors. Cell Oncol 2006; 28: 305-13.
10. Raman V, Martensen SA, Reisman D et. al. Compromised HOXA5 function can limit p53 expression in human breast tumours. Nature 2000; 405: 974-8.
11. Stasinopoulos IA, Mironchik Y, Raman A, Wildes F, Winnard PJ, Raman V. HOXA5 -twist interaction alters p53 homeostasis in breast cancer cells. J Biol Chem 2005; 280: 2294-9.
12. 2 cell cycle checkpoint associated with overexpression of HSIX1: A possible mechanism of breast carcinogenesis. Proc Natl Acad Sci USA 1998; 95: 12.608-13.
13. Ford HL, Landesman-Bollag E, Dacwag CS, Stukenberg PT, Pardee AB, Seldin DC. Cell cycle-regulated phosphorylation of the human SIX1 homeodomain protein. J Biol Chem 2000; 275: 22.245-54.
14. Fu S, Stevenson H, Strovel JW et. al. Distinct functions of two isoforms of a homeobox gene, BP1 and DLX7, in the regulation of the beta-globin gene. Gene 2001; 278: 131-9.
15. Mpolo MS, Beaudoin M, Berg PE, Beauchemin H, D'Agati V, Trudel M. BP1 is a negative modulator of definitive erythropoiesis. Nucl Acids Res 2006; 34: 5232-7.
16. Chase MB, Fu S, Haga SB et. al. BP1, a homeodomain-containing isoform of DLX4, represses the β-globin gene. Mol Cell Biol 2002; 22: 2505-14.
17. Fu SW, Schwartz A, Stevenson H et. al. Correlation of expression of BP1, a homeobox gene, with estrogen receptor status in breast cancer. Breast Cancer Res 2003; 5: R82-7.
18. Harvey JM, Clark GM, Osborne CK et. al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474-81.
19. Haga SB, Fu S, Karp JE et. al. BP1, a new homeobox gene, is frequently expressed in acute leukemias. Leukemia 2000; 14: 1867-75.
20. Yu M, Yang Y, Niu RF et. al. Clinicopathological significance of homeobox gene BP1 mRNA expression in human breast cancer. Chin J Cancer 2004; 23: 855-9.
21. Wild P, Knuechel R, Dietmaier W, Hofstaedter F, Hartmann A. Laser microdissection and microsatellite analyses of breast cancer reveal a high degree of tumor heterogeneity. Pathobiology 2000; 68: 180-90.
22. Bertheau P, Plassa LF, Lerebours F et. al. Allelic loss detection in inflammatory breast cancer: Improvement with laser microdissection. Lab Invest 2001; 81: 1397-402.
23. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-10.
24. Yu M, Shi Y, Wei X et. al. Depletion of mitochondrial DNA by ethidium bromide treatment inhibits the proliferation and tumorigenesis of T47D human breast cancer cells. Toxicol Lett 2007; 170: 83-93.
25. Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007; 8: 235-44.
26. Man YG, Fu SW, Schwartz A, Pinzone JJ, Simmens SJ, Berg PE. Expression of BP1, a novel homeobox gene, correlates with breast cancer progression and invasion. Breast Cancer Res Treat 2005; 90: 241-7.
27. Chen H, Sukumar S. Role of homeobox genes in normal mammary gland development and breast tumorigenesis. J Mammary Gland Biol Neoplasia 2003; 8: 159-75.
28. Abate-Shen C. Homeobox genes and cancer: New OCTaves for an old tune. Cancer Cell 2003; 4: 329-30.
29. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. New Engl J Med 2006; 354: 270-82.
30. Stein RA, McDonnell DP. Estrogen-related receptor alpha as a therapeutic target in cancer. Endocr Relat Cancer 2006; 13: S25-32.
31. Song YC, Fu SD, Wen XP, Ma ZH, Dang CX. Expression and significance of BP1 gene and cyclin D1 gene in breast cancer. Chin J Cancer 2007; 26: 709-14.
32. Visvader JE, Lindeman GJ. Transcriptional regulators in mammary gland development and cancer. Int J Biochem Cell Biol 2003; 35: 1034-51.
33. Xu Y, Yao L, Li H et. al. Presence of erbB2 mRNA in the plasma of breast cancer patients is associated with circulating tumor cells and negative estrogen and progesterone receptor status. Breast Cancer Res Treat 2006; 97: 49-55.
34. Orsetti B, Courjal F, Cuny M, Rodriguez C, Theillet C. 17q21-q25 aberrations in breast cancer: Combined allelotyping and CGH analysis reveals 5 regions of allelic imbalance among which two correspond to DNA amplification. Oncogene 1999; 18: 6262-70.